Thank you Madrigal for your support on this Journal Club Video Module.

In this expert journal club summary, Dr. Meena Bansal—System Chief for the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai and Director of the MASH Center of Excellence—explains the significance of the newly adopted nomenclature for fatty liver disease. She reviews the multi-society Delphi consensus statement that led to the transition from NAFLD/NASH to MASLD/MASH, emphasizing the need to remove stigmatizing language and more accurately reflect the metabolic underpinnings of the disease. Dr. Boshell highlights the international collaboration behind the change, involving 56 countries, patient advocacy groups, and leading researchers. This video explores the rationale behind using the umbrella term “steatotic liver disease,” the inclusion of MetALD to reflect patients with both metabolic dysfunction and alcohol use, and how this new framework supports future research in genomics, proteomics, and precision medicine. Tune in to learn how this global consensus is shaping the future of liver disease classification and clinical trials.